| metastatic/advanced NSCLC (mNSCLC) - 1st line (L1) | metastatic/advanced NSCLC (mNSCLC) - 2nd line (L2) | |||
| mNSCLC - L1 - PDL1 positive | non squamous - mNSCLC - L1 - Wild Type (WT) | squamous - mNSCLC - L1 - all population | mNSCLC - L2 - PDL1 positive | |
| pembrolizumab based treatment | ||||
| pembrolizumab alone | KEYNOTE-024 ... KEYNOTE-042 ... KEYNOTE-042 ... KEYNOTE-042 ... | |||
| pembrolizumab (10mg/kg) | KEYNOTE-010 ... KEYNOTE-010 ... | |||
| pembrolizumab (2mg/kg) | KEYNOTE-010 ... KEYNOTE-010 ... | |||
| pembrolizumab and pemetrexed plus platin | KEYNOTE-021 | |||
| pembrolizumab plus SoC | KEYNOTE-189 | KEYNOTE-407 | ||
Study type:
delta: difference in rate or median (if available)
-
About us
-
Contact us
-
Method
-
RSS
Made with
in Lyon
-
Credits
-
Privacy policy
-
